3D‐Architected Alkaline‐Earth Perovskites

3D ceramic architectures are captivating geometrical features with an immense demand in optics. In this work, an additive manufacturing (AM) approach for printing alkaline-earth perovskite 3D microarchitectures is developed. The approach enables custom-made photoresists suited for two-photon lithography, permitting the production of alkaline-earth perovskite (BaZrO 3, CaZrO 3, and SrZrO 3) 3D structures shaped in the form of octet-truss lattices, gyroids, or inspired architectures like sodalite zeolite, and C 60 buckyballs with micrometric and nanometric feature sizes. Alkaline-earth perovskite morphological, structural, and chemical characteristics are studied. The optical properties of such perovskite architectures are investigated using cathodoluminescence and wide-field photoluminescence emission to estimate the lifetime rate and defects in BaZrO 3, CaZrO 3, and SrZrO 3. From a broad perspective, this AM methodology facilitates the production of 3D-structured mixed oxides. These findings are the first steps toward dimensionally refined high-refractive-index ceramics for micro-optics and other terrains like (photo/electro)catalysis.</p

Diseño de un modelo de innovación enfocado en la obtención de energías renovables

Currently there is a problem related to the lack of applicable innovation models in small and medium-sized companies, which allow the generation of technologies based on renewable energies, which are a solution to the energy demand in recent decades. This article presents the development of an innovation model focused on the generation of technologies for the production of renewable energies. For this, the state of the art of the existing models was analyzed, which allowed us to observe that there were no models applicable to small companies focused on this type of energy. A flexible and easy-to-apply innovation model was created, which integrates features of the fourth and fifth generation network and integrated models, which has already been tested. Unlike other models designed for large companies, the proposed model is easily understandable, being able to be developed step by step, for a successful application, and avoiding biases, presenting an advantage over other models. This innovation model can serve as a guide for the implementation, creation and improvement of technologies for renewable energy generation systems, and covers the fields necessary for successful innovation management.En la actualidad existe una problemática relacionada con la falta de modelos de innovación enfocado a las energías renovables, que permitan generar nueva tecnología, lo cual es una solución a la demanda de energía creciente en las últimas décadas. Este articulo presenta el desarrollo de un modelo de innovación enfocado en la generación de tecnologías para la producción de energías renovables. Para ello se analizó el estado del arte de los modelos existentes, lo que permitió observar que no existían modelos aplicables a pequeñas empresas enfocados en este tipo de energías. Se creó un modelo de innovación flexible y de fácil aplicación, el cual integra características de los modelos de red e integrados de cuarta y quinta generación, el cual ya fue puesto a prueba. A diferencia de otros modelos diseñados para empresas de gran tamaño, el modelo propuesto es fácilmente entendible, pudiéndose desarrollar paso a paso, para una aplicación exitosa, y evitando sesgos, presentando una ventaja frente a otros modelos. Este modelo de innovación puede servir de guía para la implementación, creación y mejora de tecnologías para sistemas de generación de energía renovable, y abarca los campos necesarios para tener una gestión de la innovación exitosa

MPK6, sphinganine and the \u3ci\u3eLCB2a\u3c/i\u3e gene from serine palmitoyltransferase are required in the signaling pathway that mediates cell death induced by long chain bases in \u3ci\u3eArabidopsis\u3c/i\u3e

• Long chain bases (LCBs) are sphingolipid intermediates acting as second messengers in programmed cell death (PCD) in plants. Most of the molecular and cellular features of this signaling function remain unknown. • We induced PCD conditions in Arabidopsis thaliana seedlings and analyzed LCB accumulation kinetics, cell ultrastructure and phenotypes in serine palmitoyltransferase (spt), mitogen-activated protein kinase (mpk), mitogenactivated protein phosphatase (mkp1) and lcb-hydroxylase (sbh) mutants. • The lcb2a-1 mutant was unable to mount an effective PCD in response to fumonisin B1 (FB1), revealing that the LCB2a gene is essential for the induction of PCD. The accumulation kinetics of LCBs in wild-type (WT) and lcb2a-1 plants and reconstitution experiments with sphinganine indicated that this LCB was primarily responsible for PCD elicitation. The resistance of the null mpk6 mutant to manifest PCD on FB1 and sphinganine addition and the failure to show resistance on pathogen infection and MPK6 activation by FB1 and LCBs indicated that MPK6 mediates PCD downstream of LCBs. • This work describes MPK6 as a novel transducer in the pathway leading to LCBinduced PCD in Arabidopsis, and reveals that sphinganine and the LCB2a gene are required in a PCD process that operates as one of the more effective strategies used as defense against pathogens in plants

Maternal serum angiopoietin-like 3 levels in healthy and mild preeclamptic pregnant women

Objective: Angiopoietin-like protein 3(ANGPTL3) is an important regulator of lipoprotein metabolism in the fed state by inhibiting the enzyme lipoprotein lipase in oxidative tissues. However, the possible role of ANGPTL3 throughout gestation and its relationship with hormonal and biochemical variables are still unknown. The aim of this study was to determinate serum ANGPTL3 level in healthy non-pregnant women, during healthy and preeclamptic pregnancy and postpartum. Methods: Serum ANGPTL3 was analyzed by enzyme-linked immunosorbent assay (ELISA), in a prospective cohort of healthy pregnant women (n = 52) and women with mild preeclampsia (n = 21), and women at three months postpartum (n = 20) and healthy non-pregnant women (n = 20). The results obtained were correlated with biochemical, hormonal and anthropometric variables and insulin resistance indices. Results: Levels of ANGPTL3 were not different between the follicular and the luteal phases of the cycle in healthy non-pregnant women. There was a significant reduction in serum ANGPTL3 levels from the first to the third trimester in healthy pregnant women compared with healthy non-pregnant and postpartum women (p 0.05) Conclusions: We describe for the first time the profile of ANGPTL3 throughout pregnancy and postpartum as well as and discussed about explore their potential contribution interactions with lipoprotein metabolism throughout pregnancy and postpartum. Thus, low levels of ANGPTL3 during pregnancy might favor lipid uptake in oxidative tissues as the main maternal energy source, while may helping to preserve glucose for use by the fetus and placenta.Fil: Garces, María Fernanda. Universidad Nacional de Colombia; ColombiaFil: Rodriguez Navarro, Haiver Antonio. Universidad Nacional de Colombia; ColombiaFil: Buell Acosta, Julieth Daniela. Universidad Nacional de Colombia; ColombiaFil: Burgos Cardenas, Alvaro Javier. Universidad Nacional de Colombia; ColombiaFil: Franco Vega, Roberto. Universidad Nacional de Colombia; ColombiaFil: Maldonado Acosta, Luis Miguel. Universidad Nacional de Colombia; ColombiaFil: Eslava Schmalbach, Javier. Universidad Nacional de Colombia; ColombiaFil: Parada Baños, Arturo José. Universidad Nacional de Colombia; ColombiaFil: Castro Pinzon, Andres. Universidad Nacional de Colombia; ColombiaFil: Sanchez, Elizabeth. Universidad Nacional de Colombia; ColombiaFil: Angel Muller, Edith. Universidad Nacional de Colombia; ColombiaFil: Lacunza, Ezequiel. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Investigaciones Inmunológicas Básicas y Aplicadas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFil: Castaño, Justo P.. Universidad de Córdoba; EspañaFil: Dieguez, Carlos. Universidad de Santiago de Compostela; EspañaFil: Nogueiras, Rubén. Universidad de Santiago de Compostela; EspañaFil: Ruiz Parra, Ariel Ivan. Universidad Nacional de Colombia; ColombiaFil: Caminos, Jorge Eduardo. Universidad Nacional de Colombia; Colombi

Studies on human papillomavirus (HPV) in Ecuador, part I

Aprovechando la realización de las XL Jornadas Nacionales de Biología Espol en la ciudad de Guayaquil, se realizó una sesión dedicada a la epidemiología del virus de papiloma humano (VPH) y del cáncer cervical. Esta sesión tuvo la participación de varios investigadores provenientes de diferentes zonas del Ecuador. El presente artículo tiene como objeto presentar un resumen de estas charlas, junto a un análisis de la información mostrada además de una reflexión sobre las preguntas que quedan aún por responder en cuanto al perfil epidemiológico de esta patología en el país.Taking advantage of the realization of the XL National Conference on Espol Biology in the city of Guayaquil, a session was held dedicated to the epidemiology of Human Papilloma Virus (HPV) and cervical cancer. This session was attended by several researchers from different areas of Ecuador. The object of this article is to present a summary of these talks, together with an analysis of the information shown in addition to a reflection on the questions still to be answered regarding the epidemiological profile of this pathology in the country.Fil: Rivera, Angélica. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: De la Plata, Janice. Escuela Superior Politécnica del Litoral. Facultad de Ciencias de la Vida; EcuadorFil: Montiel, Marynes. Escuela Superior Politécnica del Litoral. Facultad de Ciencias de la Vida; EcuadorFil: Romero, Christian. Escuela Superior Politécnica del Litoral. Facultad de Ciencias de la Vida; EcuadorFil: Piedrahíta, Paolo. Escuela Superior Politécnica del Litoral. Facultad de Ciencias de la Vida; EcuadorFil: Sanchez, Eduardo. Escuela Superior Politécnica del Litoral. Facultad de Ciencias de la Vida; EcuadorFil: Moreno, Arturo. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Espinosa, Maylen. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Bedoya, César. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Arreaga, Carlos. Universidad Técnica de Machala; EcuadorFil: España, Karool. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Parrales, Eduardo. Universidad de Guayaquil; EcuadorFil: Zhingre, Alicia. Universidad de Guayaquil; EcuadorFil: Sanchez, Sunny. Universidad de Especialidades Espíritu Santo; EcuadorFil: Campoverde, Alfredo. Universidad de Cuenca; EcuadorFil: Dalgo, Paola. Universidad Técnica Particular de Loja; EcuadorFil: Arévalo, Paulina. Universidad Técnica Particular de Loja; EcuadorFil: García, Gustavo. Sociedad de Lucha Contra el Cáncer. Instituto Oncológico Nacional; EcuadorFil: Mendoza, Marcia. Sociedad de Lucha Contra el Cáncer. Instituto Oncológico Nacional; EcuadorFil: Ruiz, Juan. Sociedad de Lucha Contra el Cáncer. Instituto Oncológico Nacional; EcuadorFil: Sanchez, Martha. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Medina, Lex. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Párraga, Karla. United European Gastroenterology; AustriaFil: Ibarra, Alejandra. Universidad Nacional de Misiones. Facultad de Ciencias Exactas, Químicas y Naturales; ArgentinaFil: Quimís, María. No especifíca;Fil: Parrales, Johana. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Molina, Denisse. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Badano, Ines. Universidad Nacional de Misiones. Facultad de Ciencias Exactas, Químicas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; ArgentinaFil: Orlando, Alberto. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; EcuadorFil: Vega Luzuriaga, Patricio. Ministerio de Salud Publica. Instituto Nacional de Investigacion En Salud Publica Dr. Leopoldo Izquieta Perez; Ecuado

INNOVASONORA: desarrollo de recursos para la transmisión digital de los archivos sonoros y la aplicación de la realidad virtual como complemento de la enseñanza presencial

Memoria del proyecto de innovación docente nº 208 (curso 2020-2021

INNOVASONORA: gestión de archivos sonoros, sonido inmersivo y realidad virtual en plataformas LMS

Memoria del proyecto de innovación docente "Innovasonora" (Curso 2021-2022

El laboratorio sonoro como herramienta docente para el análisis de la creación e interpretación musical a través de las grabaciones

Depto. de MusicologíaFac. de Geografía e HistoriaFALSEsubmitte

Variation in Structure and Process of Care in Traumatic Brain Injury: Provider Profiles of European Neurotrauma Centers Participating in the CENTER-TBI Study.

INTRODUCTION: The strength of evidence underpinning care and treatment recommendations in traumatic brain injury (TBI) is low. Comparative effectiveness research (CER) has been proposed as a framework to provide evidence for optimal care for TBI patients. The first step in CER is to map the existing variation. The aim of current study is to quantify variation in general structural and process characteristics among centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. METHODS: We designed a set of 11 provider profiling questionnaires with 321 questions about various aspects of TBI care, chosen based on literature and expert opinion. After pilot testing, questionnaires were disseminated to 71 centers from 20 countries participating in the CENTER-TBI study. Reliability of questionnaires was estimated by calculating a concordance rate among 5% duplicate questions. RESULTS: All 71 centers completed the questionnaires. Median concordance rate among duplicate questions was 0.85. The majority of centers were academic hospitals (n = 65, 92%), designated as a level I trauma center (n = 48, 68%) and situated in an urban location (n = 70, 99%). The availability of facilities for neuro-trauma care varied across centers; e.g. 40 (57%) had a dedicated neuro-intensive care unit (ICU), 36 (51%) had an in-hospital rehabilitation unit and the organization of the ICU was closed in 64% (n = 45) of the centers. In addition, we found wide variation in processes of care, such as the ICU admission policy and intracranial pressure monitoring policy among centers. CONCLUSION: Even among high-volume, specialized neurotrauma centers there is substantial variation in structures and processes of TBI care. This variation provides an opportunity to study effectiveness of specific aspects of TBI care and to identify best practices with CER approaches

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection